CDSCO Panel Recommends Protocol Amendment for Novartis' Ianalumab Trial
New Delhi: The Subject Expert Committee (SEC) on Haematology, functional under the Central Drugs Standard Control Organisation (CDSCO) has recommended for approval of a protocol amendment in an ongoing global clinical trial of Ianalumab (VAY736) by Novartis Healthcare Private Limited.
The matter was taken up during the 4th SEC (Haematology) meeting of 2025 held on April 8 at CDSCO headquarters, New Delhi. According to the official minutes,
“The firm presented protocol amendment version 05 dated 27 January 2025 protocol no. CVAY736I12301. After detailed deliberation, the committee recommended for approval of protocol amendment as presented by the firm.”
Ianalumab, a monoclonal antibody targeting BAFF-R, is under global investigation for a range of autoimmune and hematological conditions.
Also Read: CDSCO Panel Demands Structured Phase IV Protocol for Ademetionine in Liver Disease Subtypes
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.